WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H564003
CAS#: 1825302-42-8
Description: H3B-8800, also known as RVT-2001, is an orally available small-molecule splicing modulator (SF3b Modulator). H3B-8800 induces lethality in spliceosome-mutant cancers. H3B-8800 potently and preferentially kills spliceosome-mutant epithelial and hematologic tumor cells. These killing effects of H3B-8800 are due to its direct interaction with the SF3b complex, as evidenced by loss of H3B-8800 activity in drug-resistant cells bearing mutations in genes encoding SF3b components. H3B-8800 displayed preferential lethality towards SF3B1-mutated cells and synergism with the BCL2 inhibitor venetoclax, supporting the potential use of SF3B1 inhibitors as a novel therapeutic strategy in CLL.
Hodoodo Cat#: H564003
Name: H3B-8800
CAS#: 1825302-42-8
Chemical Formula: C31H45N3O6
Exact Mass: 555.33
Molecular Weight: 555.720
Elemental Analysis: C, 67.00; H, 8.16; N, 7.56; O, 17.27
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 1825302-42-8,
Synonym: H3B-8800; H3B8800; H3B 8800; RVT-2001; RVT 2001; RVT2001;
IUPAC/Chemical Name: (2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate
InChi Key: YOIQWBAHJZGRFW-WVRLKXNASA-N
InChi Code: InChI=1S/C31H45N3O6/c1-22(26-11-6-7-16-32-26)9-8-10-23(2)29-24(3)12-13-27(39-30(37)34-19-17-33(5)18-20-34)31(4,38)15-14-25(35)21-28(36)40-29/h6-13,16,22,24-25,27,29,35,38H,14-15,17-21H2,1-5H3/b9-8+,13-12+,23-10+/t22-,24+,25-,27+,29-,31-/m1/s1
SMILES Code: O=C(N1CCN(C)CC1)O[C@H]([C@](C)(O)CC[C@@H](O)C2)/C=C/[C@H](C)[C@@H](/C(C)=C/C=C/[C@H](C3=NC=CC=C3)C)OC2=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: The SF3B1 protein, part of the SF3b complex, recognizes the intron branch point sequence of precursor messenger RNA (pre-mRNA), thus contributing to splicing fidelity. SF3B1 is frequently mutated in cancer and is the target of distinct families of splicing modulators (SMs)
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 555.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: López-Oreja I, Gohr A, Playa-Albinyana H, Giró A, Arenas F, Higashi M, Tripathi R, López-Guerra M, Irimia M, Aymerich M, Valcárcel J, Bonnal S, Colomer D. SF3B1 mutation-mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia. Life Sci Alliance. 2023 Aug 10;6(11):e202301955. doi: 10.26508/lsa.202301955. PMID: 37562845; PMCID: PMC10415613.
2: Morales ML, García-Vicente R, Rodríguez-García A, Reyes-Palomares A, Vincelle-Nieto Á, Álvarez N, Ortiz-Ruiz A, Garrido-García V, Giménez A, Carreño- Tarragona G, Sánchez R, Ayala R, Martínez-López J, Linares M. Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia. Leukemia. 2023 Aug;37(8):1649-1659. doi: 10.1038/s41375-023-01963-4. Epub 2023 Jul 8. PMID: 37422594; PMCID: PMC10400425.
3: Spinello A, Borišek J, Malcovati L, Magistrato A. Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in Spliceosome-Mutant Cancers. Int J Mol Sci. 2021 Oct 18;22(20):11222. doi: 10.3390/ijms222011222. PMID: 34681880; PMCID: PMC8540225.
4: Sim J, Jang E, Kim HJ, Jeon H. Total Syntheses of Pladienolide-Derived Spliceosome Modulators. Molecules. 2021 Sep 30;26(19):5938. doi: 10.3390/molecules26195938. PMID: 34641481; PMCID: PMC8512135.
5: Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25. PMID: 34172893; PMCID: PMC8632688.
6: Rhoades D, Rheingold AL, O'Malley BW, Wang J. Expedient Total Syntheses of Pladienolide-Derived Spliceosome Modulators. J Am Chem Soc. 2021 Apr 7;143(13):4915-4920. doi: 10.1021/jacs.1c01135. Epub 2021 Mar 23. PMID: 33755462.
7: Saygin C, Carraway HE. Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791. doi: 10.1016/j.blre.2020.100791. Epub 2020 Dec 27. PMID: 33423844.
8: Zhang D, Meng F. A Comprehensive Overview of Structure-Activity Relationships of Small-Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents. ChemMedChem. 2020 Nov 18;15(22):2098-2120. doi: 10.1002/cmdc.202000642. Epub 2020 Oct 22. PMID: 33037739.
9: Zhou Y, Han C, Wang E, Lorch AH, Serafin V, Cho BK, Gutierrez Diaz BT, Calvo J, Fang C, Khodadadi-Jamayran A, Tabaglio T, Marier C, Kuchmiy A, Sun L, Yacu G, Filip SK, Jin Q, Takahashi YH, Amici DR, Rendleman EJ, Rawat R, Bresolin S, Paganin M, Zhang C, Li H, Kandela I, Politanska Y, Abdala-Valencia H, Mendillo ML, Zhu P, Palhais B, Van Vlierberghe P, Taghon T, Aifantis I, Goo YA, Guccione E, Heguy A, Tsirigos A, Wee KB, Mishra RK, Pflumio F, Accordi B, Basso G, Ntziachristos P. Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia. Cancer Discov. 2020 Sep;10(9):1388-1409. doi: 10.1158/2159-8290.CD-19-1436. Epub 2020 May 22. PMID: 32444465; PMCID: PMC7483384.
10: Eymin B. Targeting the spliceosome machinery: A new therapeutic axis in cancer? Biochem Pharmacol. 2021 Jul;189:114039. doi: 10.1016/j.bcp.2020.114039. Epub 2020 May 15. PMID: 32417188.
11: Rioux N, Smith S, Colombo F, Kim A, Lai WG, Nix D, Siu YA, Schindler J, Smith PG. Metabolic disposition of H3B-8800, an orally available small-molecule splicing modulator, in rats, monkeys, and humans. Xenobiotica. 2020 Sep;50(9):1101-1114. doi: 10.1080/00498254.2019.1709134. Epub 2020 Jan 6. PMID: 31902291.
12: Pellagatti A, Boultwood J. Splicing factor mutant myelodysplastic syndromes: Recent advances. Adv Biol Regul. 2020 Jan;75:100655. doi: 10.1016/j.jbior.2019.100655. Epub 2019 Sep 19. PMID: 31558432.
13: Aujla A, Linder K, Iragavarapu C, Karass M, Liu D. SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms. Biomark Res. 2018 Sep 26;6:29. doi: 10.1186/s40364-018-0142-y. PMID: 30275952; PMCID: PMC6158887.
14: Steensma DP. An RNA bestiary in splicing-mutant MDS. Blood. 2018 Sep 20;132(12):1217-1219. doi: 10.1182/blood-2018-07-859942. PMID: 30237252.
15: A Small-Molecule Splicing Modulator Targets Spliceosome-Mutant Cells. Cancer Discov. 2018 Apr;8(4):384. doi: 10.1158/2159-8290.CD-RW2018-038. Epub 2018 Mar 2. PMID: 29500297.
16: Finci LI, Zhang X, Huang X, Zhou Q, Tsai J, Teng T, Agrawal A, Chan B, Irwin S, Karr C, Cook A, Zhu P, Reynolds D, Smith PG, Fekkes P, Buonamici S, Larsen NA. The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action. Genes Dev. 2018 Feb 1;32(3-4):309-320. doi: 10.1101/gad.311043.117. PMID: 29491137; PMCID: PMC5859971.
17: Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel- Wahab O, Smith PG, Buonamici S. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018 May;24(4):497-504. doi: 10.1038/nm.4493. Epub 2018 Feb 19. PMID: 29457796; PMCID: PMC6730556.
18: Montalban-Bravo G, Garcia-Manero G, Jabbour E. Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. Curr Opin Hematol. 2018 Mar;25(2):146-153. doi: 10.1097/MOH.0000000000000400. PMID: 29266015.
